A citation-based method for searching scientific literature

Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski, Carola Huthmacher, Emma Gudgin, Dave Lugo, Soren Beinke, Trevor D Chapman, Emma J Roberts, Peter E Soden, Kurt R Auger, Olivier Mirguet, Konstanze Doehner, Ruud Delwel, Alan K Burnett, Phillip Jeffrey, Gerard Drewes, Kevin Lee, Brian J P Huntly, Tony Kouzarides. Nature 2011
Times Cited: 1030







List of co-cited articles
1296 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
44

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
42

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
37

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011
770
33

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
24

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005
816
23

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016
252
22

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
21


BET inhibitor resistance emerges from leukaemia stem cells.
Chun Yew Fong, Omer Gilan, Enid Y N Lam, Alan F Rubin, Sarah Ftouni, Dean Tyler, Kym Stanley, Devbarna Sinha, Paul Yeh, Jessica Morison,[...]. Nature 2015
325
18

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid Y N Lam, Chun-Wa Chung, Paul Bamborough, Massimo Petretich,[...]. Science 2020
108
17

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
884
15

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
104
15

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
Zhiyuan Yang, Jasper H N Yik, Ruichuan Chen, Nanhai He, Moon Kyoo Jang, Keiko Ozato, Qiang Zhou. Mol Cell 2005
747
15

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae-Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny-Reiterer, Barbara Peter, Julian Jude,[...]. Nature 2015
301
15

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
141
14

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
14

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013
13

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
324
13

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
769
13

Functions of bromodomain-containing proteins and their roles in homeostasis and cancer.
Takao Fujisawa, Panagis Filippakopoulos. Nat Rev Mol Cell Biol 2017
230
12

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016
242
12

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
M A Dawson, E J Gudgin, S J Horton, G Giotopoulos, E Meduri, S Robson, E Cannizzaro, H Osaki, M Wiese, S Putwain,[...]. Leukemia 2014
130
12

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.
Michael I Love, Wolfgang Huber, Simon Anders. Genome Biol 2014
12


Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Jeremy Lewin, Jean-Charles Soria, Anastasios Stathis, Jean-Pierre Delord, Solange Peters, Ahmad Awada, Philippe G Aftimos, Mohamed Bekradda, Keyvan Rezai, Zhen Zeng,[...]. J Clin Oncol 2018
98
10

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014
581
10

The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.
Shaila Rahman, Mathew E Sowa, Matthias Ottinger, Jennifer A Smith, Yang Shi, J Wade Harper, Peter M Howley. Mol Cell Biol 2011
316
10

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Kathrin M Bernt, Nan Zhu, Amit U Sinha, Sridhar Vempati, Joerg Faber, Andrei V Krivtsov, Zhaohui Feng, Natalie Punt, Amanda Daigle, Lars Bullinger,[...]. Cancer Cell 2011
576
9

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Garrett W Rhyasen, Maureen M Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L Dale, Scott Boiko, Tony Cheung, Jingwen Zhang,[...]. Mol Cancer Ther 2016
82
10

Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation.
Friederike Itzen, Ann Katrin Greifenberg, Christian A Bösken, Matthias Geyer. Nucleic Acids Res 2014
119
9

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Jean-Philippe Lambert, Sarah Picaud, Takao Fujisawa, Huayun Hou, Pavel Savitsky, Liis Uusküla-Reimand, Gagan D Gupta, Hala Abdouni, Zhen-Yuan Lin, Monika Tucholska,[...]. Mol Cell 2019
63
14

Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.
Sven Heinz, Christopher Benner, Nathanael Spann, Eric Bertolino, Yin C Lin, Peter Laslo, Jason X Cheng, Cornelis Murre, Harinder Singh, Christopher K Glass. Mol Cell 2010
9


BET Proteins as Targets for Anticancer Treatment.
Anastasios Stathis, Francesco Bertoni. Cancer Discov 2018
178
9

STAR: ultrafast universal RNA-seq aligner.
Alexander Dobin, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, Thomas R Gingeras. Bioinformatics 2013
9

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Phillippe A Cassier, Victor Moreno, Johann S de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady,[...]. JNCI Cancer Spectr 2019
48
18

Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.
Jian Shi, Yifan Wang, Lei Zeng, Yadi Wu, Jiong Deng, Qiang Zhang, Yiwei Lin, Junlin Li, Tiebang Kang, Min Tao,[...]. Cancer Cell 2014
280
9

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016
8

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Christina R Majer, Christopher J Sneeringer, Jeffrey Song, L Danielle Johnston, Margaret Porter Scott, Jesse J Smith, Yonghong Xiao,[...]. Cancer Cell 2011
629
8

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.
Konstantinos Tzelepis, Hiroko Koike-Yusa, Etienne De Braekeleer, Yilong Li, Emmanouil Metzakopian, Oliver M Dovey, Annalisa Mupo, Vera Grinkevich, Meng Li, Milena Mazan,[...]. Cell Rep 2016
258
8

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Aravind Basavapathruni, Lei Jin, P Ann Boriack-Sjodin, Christina J Allain, Christine R Klaus, Alejandra Raimondi, Margaret Porter Scott,[...]. Blood 2013
443
8

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
151
8

The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis.
Anup Dey, Farideh Chitsaz, Asim Abbasi, Tom Misteli, Keiko Ozato. Proc Natl Acad Sci U S A 2003
442
8

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015
166
8

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Brian K Albrecht, Victor S Gehling, Michael C Hewitt, Rishi G Vaswani, Alexandre Côté, Yves Leblanc, Christopher G Nasveschuk, Steve Bellon, Louise Bergeron, Robert Campbell,[...]. J Med Chem 2016
107
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala,[...]. Nat Med 2015
235
8

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
118
8

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Georg E Winter, Andreas Mayer, Dennis L Buckley, Michael A Erb, Justine E Roderick, Sarah Vittori, Jaime M Reyes, Julia di Iulio, Amanda Souza, Christopher J Ott,[...]. Mol Cell 2017
168
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.